Navigation Links
Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
Date:8/4/2010

JUPITER, Fla., Aug. 4 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today that the United States District Court for the Southern District of Florida has approved the final resolution of the consolidated stockholder class action lawsuit, Miller v. Dyadic International, Inc. et al, and dismissed the lawsuit with prejudice.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO )

The lawsuit initially filed in October 2007 asserted class action claims under federal securities laws based on allegations of misstatements and omissions by Dyadic and certain of its current and former officers and directors arising out of alleged improprieties at Dyadic's Asian subsidiaries.  As reported in Dyadic's latest consolidated financial statements, Dyadic established a cash reserve in connection with the class action lawsuit which adequately covers the costs associated with resolving this matter.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "We are pleased to put this matter behind us so we can continue focusing on growing our business through the ongoing sale of enzymes and the monetization of our C1 platform technology through potential licensing arrangements and other collaborations."

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzyme products and solutions to address the needs of the bioenergy, biopharmaceutical and industrial enzyme markets. Please visit Dyadic's website at www.dyadic.com

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Engages The Abraham Group as Strategic Advisor
2. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
3. Dyadic International Strengthens Management Team
4. Dyadic International Extends Collaboration With The Scripps Research Institute
5. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
6. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
7. FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. Bacterin International Appoints Three New Members to Its Board of Directors
10. THE PLANNING SHOP international Announces Oncology Business Unit
11. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Malden, MA (PRWEB) , ... February 24, 2017 ... ... disc replacement (TDR) procedures can be safely completed in an ambulatory surgery center ... and fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)...  Driven by consumers, preference towards more natural ... growing categories, finds the recently published U.S. volume ... Multi-regional Market Analysis and Opportunities study by ... "Biotechnology actives are derived from natural ... for skin and hair care applications," explains ...
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
Breaking Biology Technology:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
Breaking Biology News(10 mins):